98%
921
2 minutes
20
Objective: Microvascular invasion (MVI) is a risk factor for disease recurrence and worse survival in hepatocellular carcinoma (HCC) patients after radical resection. This study aimed to investigate the efficacy of prophylactic transarterial chemoembolization (TACE) after R0 resection in HCC patients with MVI.
Methods: A total of 130 HCC patients with MVI who received R0 resection were retrospectively analyzed, and categorized into TACE (n = 73) and non-TACE (n = 57) groups according to whether prophylactic TACE after R0 resection was performed or not. Tumor recurrence, death, recurrence-free survival (RFS), and overall survival (OS) were evaluated.
Results: Tumor grading (P = 0.001), minor axis of tumor (P = 0.017), neutrophil (P = 0.029), and aspartate aminotransferase (P = 0.014) were higher in TACE group compared to non-TACE group at baseline, indicating a worse baseline disease condition in TACE group. During the follow up, tumor recurrence rate (56.2% versus 61.4%, P = 0.548), mortality rate (37.0% vs. 43.9%, P = 0.427), RFS (median: 44.0 versus 37.0 months, P = 0.325), and OS (median not reached in both groups, P = 0.355) were not different between TACE and non-TACE groups. Considering the worse baseline disease condition in TACE group versus non-TACE group as confounding factor, that affects the evaluation of efficacy; the multivariable Cox regression analyses were performed for adjustment, which revealed that group (TACE versus non-TACE) was independently correlated with prolonged RFS (P = 0.007, HR = 0.447, 95% CI: 0.248-0.804) and OS (P = 0.001, HR = 0.260, 95% CI: 0.116-0.583).
Conclusion: Prophylactic TACE after R0 resection is beneficial to improve the prognosis in HCC patients with MVI. However, further large-scale, randomized, controlled studies are needed for verification.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12133621 | PMC |
http://dx.doi.org/10.1007/s12672-025-02722-w | DOI Listing |
Ann Surg Oncol
September 2025
Department of Hepatobiliary Surgery, Eastern Hepatobiliary Surgery Hospital, Naval Medical University, Shanghai, China.
Background: Postoperative late recurrence (POLAR) after 2 years from the date of surgical resection of hepatocellular carcinoma (HCC) represents a unique surveillance and management challenge. Despite identified risk factors, individualized prediction tools to guide personalized surveillance strategies for recurrence remain scarce. The current study sought to develop a predictive model for late recurrence among patients undergoing HCC resection.
View Article and Find Full Text PDFJ Hepatocell Carcinoma
September 2025
Department of Liver Disease, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, People's Republic of China.
Objective: Anoikis is an anchorage-dependent programmed cell death implicated in multiple pathological processes of cancers; however, the prognostic value of anoikis-related genes (ANRGs) in hepatocellular carcinoma (HCC) remains unclear. Our study aims to develop an ANRGs-based prediction model to improve prognostic assessment in HCC patients.
Methods: The RNA-seq profile was performed to estimate the expression of ANRGs in HCC patients.
Immunotargets Ther
September 2025
Department of Interventional Radiology, the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, People's Republic of China.
Purpose: This study aimed to evaluate the clinical efficiency and safety of hepatic arterial infusion chemotherapy (HAIC) combined with lenvatinib and programmed cell death protein-1 (PD-1) inhibitor for patients with hepatocellular carcinoma (HCC) and lung metastasis.
Methods: In this multicenter retrospective study, treatment-naive patients with advanced (BCLC stage C) HCC and lung metastases who received lenvatinib and PD-1 inhibitor - with or without HAIC - between January 2019 and January 2024 were reviewed. Propensity score matching (PSM) was applied to balance baseline characteristics between the two groups.
Front Pharmacol
August 2025
The Second Affiliated Hospital of Zhejiang Chinese Medical University, TCM Hepatology Department, Hangzhou, China.
Hepatocellular carcinoma (HCC) is a prevalent malignant neoplasm of the digestive system, including 80% of primary liver malignancies. The Wnt/β-catenin signaling pathway plays a key role in immune response and tumer resistance. A growing number of studies have shown that the Wnt/β-catenin signaling pathway is involved in the pathogenesis of HCC.
View Article and Find Full Text PDFPathol Res Pract
September 2025
Chongqing Key Laboratory of Translational Research for Cancer Metastasis and Individualized Treatment, Chongqing University Cancer Hospital & Chongqing Cancer Institute & Chongqing Cancer Hospital, Chongqing 400030, China. Electronic address:
Objective: To investigate the mechanism by which C5ORF13 promotes epithelial-mesenchymal transition (EMT) in hepatocellular carcinoma (HCC) through interaction with eukaryotic translation initiation factor 6 (eIF6) and its clinical significance, and to identify the potential use of valproic acid (VPA) as an eIF6 inhibitor in HCC.
Methods: The expression of C5ORF13 in HCC and its prognostic impact were analyzed using GEPIA, UALCAN, and The HUMAN PROTEIN ATLAS databases. Lentiviral transfection technology was used to knock down or overexpress C5ORF13 and eIF6.